Skip to main
  1. Stocks
  2. Pelthos Therapeutics Inc
  3. Forecast
PTHS

PTHS Stock Forecast & Price Target

PTHS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pelthos Therapeutics is supported by a commercial portfolio with three FDA-approved products, led by ZELSUVI, whose 3Q26 revenue of $15.2M and 12,384 units dispensed show steady demand despite seasonality. Its outlook improves further from the proposed all-stock merger with Castle Creek Biosciences, which adds D-Fi, a Phase III rare-disease asset that could expand the company’s long-term revenue base while remaining aligned with its dermatology focus. Although the transaction increases dilution and R&D spend, the company’s $24M in cash in 2Q26, additional Horizon funding access, and expanding formulary coverage for about 24M lives support commercialization and pipeline execution.

Bears say

Pelthos Therapeutics is facing a weaker-than-expected commercial trajectory, as 3Q26 Zelsuvmi revenue of $15.2M fell short of both OpCo and consensus expectations, while only a 4% scripts increase and higher gross-to-net deductions limited net revenue expansion. The company’s growth profile appears to be flattening over the past 2 quarters, and management’s uncertainty into the holiday slow down suggests additional 4Q26 pressure even with a stronger October and a new PBM agreement. Fundamentally, the negative outlook is driven by dependence on successful Zelsuvmi commercialization, rising GtNs at 31.5% in 3Q26, and key risks around financing, intellectual property, regulatory/reimbursement changes, and competition.

PTHS has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

PTHS Analyst Forecast & Price Prediction

Get the latest PTHS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PTHS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pelthos Therapeutics Inc (PTHS) Forecast

Analysts have given PTHS a Buy based on their latest research and market trends.

According to 6 analysts, PTHS has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pelthos Therapeutics Inc (PTHS)


PTHS Analyst Forecast & Price Prediction

Get the latest PTHS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in PTHS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover PTHS stock data and trends